Citadel Advisors’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20.4M | Sell |
308,800
-45,600
| -13% | -$2.9M | ﹤0.01% | 2327 |
|
|
2025
Q4 | $22.5M | Buy |
354,400
+34,400
| +11% | +$2.14M | ﹤0.01% | 2208 |
|
|
2025
Q3 | $17.6M | Sell |
320,000
-23,400
| -7% | -$964K | ﹤0.01% | 2498 |
|
|
2025
Q2 | $11.3M | Buy |
343,400
+33,900
| +11% | +$1.18M | ﹤0.01% | 2849 |
|
|
2025
Q1 | $12.4M | Buy |
309,500
+138,600
| +81% | +$6.37M | ﹤0.01% | 2580 |
|
|
2024
Q4 | $8.04M | Sell |
170,900
-48,900
| -22% | -$2.54M | ﹤0.01% | 3259 |
|
|
2024
Q3 | $11.6M | Sell |
219,800
-12,100
| -5% | -$674K | ﹤0.01% | 2688 |
|
|
2024
Q2 | $12.6M | Sell |
231,900
-291,400
| -56% | -$17.6M | ﹤0.01% | 2502 |
|
|
2024
Q1 | $36.7M | Sell |
523,300
-150,800
| -22% | -$11.7M | 0.01% | 1466 |
|
|
2023
Q4 | $56.3M | Buy |
674,100
+586,600
| +670% | +$21.2M | 0.01% | 1092 |
|
|
2023
Q3 | $2.58M | Buy |
87,500
+20,000
| +30% | +$666K | ﹤0.01% | 4763 |
|
|
2023
Q2 | $2.2M | Buy |
67,500
+46,500
| +221% | +$1.72M | ﹤0.01% | 4999 |
|
|
2023
Q1 | $739K | Sell |
21,000
-24,100
| -53% | -$983K | ﹤0.01% | 7447 |
|
|
2022
Q4 | $2.07M | Buy |
45,100
+22,800
| +102% | +$981K | ﹤0.01% | 5423 |
|
|
2022
Q3 | $1.08M | Buy |
22,300
+500
| +2% | +$24.1K | ﹤0.01% | 6840 |
|
|
2022
Q2 | $857K | Buy |
21,800
+4,400
| +25% | +$177K | ﹤0.01% | 7373 |
|
|
2022
Q1 | $640K | Sell |
17,400
-7,500
| -30% | -$266K | ﹤0.01% | 8795 |
|
|
2021
Q4 | $1.14M | Sell |
24,900
-9,600
| -28% | -$370K | ﹤0.01% | 7638 |
|
|
2021
Q3 | $1.23M | Buy |
34,500
+2,000
| +6% | +$58.9K | ﹤0.01% | 7597 |
|
|
2021
Q2 | $643K | Buy |
32,500
+6,000
| +23% | +$141K | ﹤0.01% | 9445 |
|
|
2021
Q1 | $616K | Sell |
26,500
-29,900
| -53% | -$638K | ﹤0.01% | 9230 |
|
|
2020
Q4 | $1.17M | Sell |
56,400
-89,400
| -61% | -$1.63M | ﹤0.01% | 6463 |
|
|
2020
Q3 | $3.16M | Sell |
145,800
-14,400
| -9% | -$337K | ﹤0.01% | 3898 |
|
|
2020
Q2 | $3.78M | Sell |
160,200
-47,400
| -23% | -$889K | ﹤0.01% | 3486 |
|
|
2020
Q1 | $2.45M | Buy |
207,600
+70,900
| +52% | +$905K | ﹤0.01% | 3820 |
|
|
2019
Q4 | $1.45M | Buy |
+136,700
| New | +$1.4M | ﹤0.01% | 4927 |
|
|
2019
Q3 | – | Sell |
-14,600
| Closed | -$164K | – | 9243 |
|
|
2019
Q2 | $164K | Sell |
14,600
-8,900
| -38% | -$85.8K | ﹤0.01% | 8314 |
|
|
2019
Q1 | $190K | Buy |
+23,500
| New | +$173K | ﹤0.01% | 8243 |
|
|
2018
Q2 | – | Sell |
-13,600
| Closed | -$98K | – | 8884 |
|
|
2018
Q1 | $98K | Sell |
13,600
-68,000
| -83% | -$583K | ﹤0.01% | 7718 |
|
|
2017
Q4 | $665K | Buy |
81,600
+52,500
| +180% | +$596K | ﹤0.01% | 5238 |
|
|
2017
Q3 | $422K | Buy |
+29,100
| New | +$398K | ﹤0.01% | 5569 |
|
|
2016
Q2 | – | Sell |
-17,200
| Closed | -$121K | – | 6902 |
|
|
2016
Q1 | $121K | Buy |
17,200
+13,700
| +391% | +$100K | ﹤0.01% | 5941 |
|
|
2015
Q4 | $37K | Sell |
3,500
-300
| -8% | -$2.94K | ﹤0.01% | 7524 |
|
|
2015
Q3 | $25K | Sell |
3,800
-4,500
| -54% | -$30.7K | ﹤0.01% | 8029 |
|
|
2015
Q2 | $56K | Sell |
8,300
-2,600
| -24% | -$17.1K | ﹤0.01% | 7579 |
|
|
2015
Q1 | $74K | Buy |
10,900
+7,900
| +263% | +$59K | ﹤0.01% | 7104 |
|
|
2014
Q4 | $24K | Sell |
3,000
-11,000
| -79% | -$47.2K | ﹤0.01% | 7668 |
|
|
2014
Q3 | $49K | Sell |
14,000
-20,100
| -59% | -$84.4K | ﹤0.01% | 6918 |
|
|
2014
Q2 | $163K | Buy |
34,100
+33,700
| +8,425% | +$206K | ﹤0.01% | 5783 |
|
|
2014
Q1 | $4K | Buy |
+400
| New | +$3.62K | ﹤0.01% | 7677 |
|
Other funds holding CYTK
VPM
VCM
ACA
Citadel Advisors's CYTK Position: Q1 2026 in Review
Citadel Advisors reduced its Cytokinetics (CYTK) stake by 5.4% in Q1 2026, selling an estimated $4.01M and leaving 1,099,858 shares worth $72.5M. The position accounts for 0.01% of the portfolio, ranked #1052.
Citadel Advisors first reported a position in CYTK in Q1 2014 and has held it in 45 quarters since. The position peaked at $182M in Q2 2022. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.
- Citadel Advisors held 1,099,858 shares of Cytokinetics worth $72.5M as of Q1 2026.
- Citadel Advisors sold 63,079 Cytokinetics shares in Q1 2026, an estimated $4.01M.
- Cytokinetics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1052 holding.
- Citadel Advisors first reported a position in Cytokinetics in Q1 2014 and has held it in 45 quarters since.
- Citadel Advisors's Cytokinetics position peaked at $182M in Q2 2022.
- 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.